TradeLink Capital LLC purchased a new position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,842 shares of the medical research company's stock, valued at approximately $1,046,000. Bruker makes up 10.3% of TradeLink Capital LLC's holdings, making the stock its 2nd largest holding.
A number of other large investors also recently modified their holdings of BRKR. FMR LLC raised its stake in Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock worth $987,981,000 after buying an additional 2,521,904 shares during the last quarter. State Street Corp lifted its stake in shares of Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after purchasing an additional 318,808 shares during the period. RTW Investments LP boosted its position in shares of Bruker by 1.1% during the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company's stock valued at $240,406,000 after purchasing an additional 37,024 shares in the last quarter. Geode Capital Management LLC grew its stake in Bruker by 10.8% during the third quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company's stock worth $137,702,000 after purchasing an additional 193,580 shares during the period. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after purchasing an additional 666,617 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on BRKR shares. UBS Group assumed coverage on Bruker in a report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price target on the stock. Guggenheim restated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Bank of America upped their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Stifel Nicolaus reduced their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research note on Friday, February 14th. Finally, The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price on the stock in a research report on Thursday, December 5th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and a consensus price target of $70.50.
Get Our Latest Research Report on Bruker
Bruker Stock Performance
BRKR stock traded down $0.20 during midday trading on Wednesday, hitting $45.36. The company's stock had a trading volume of 515,880 shares, compared to its average volume of 1,261,564. The stock has a market cap of $6.88 billion, a price-to-earnings ratio of 59.63, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a 1 year low of $44.89 and a 1 year high of $94.86. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The stock's 50-day moving average price is $54.48 and its 200 day moving average price is $58.76.
Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, equities analysts forecast that Bruker Co. will post 2.69 EPS for the current year.
Bruker Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.44%. Bruker's dividend payout ratio is presently 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
See Also
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
